-
Efficacy and safety of bortezomib in patients with renal impairment: results from the APEX phase 3 study San Miguel JF, Richardson PG, Sonneveld P, Schuster MW, Irwin D, Stadtmauer EA, Facon T, Harousseau JL, Ben-Yehuda D, Lonial S, Goldsmidt H, Reece D, Bladé J, Boccadoro M, Cavenagh JD, Neuwirth R, Boral AL, Esseltine DL, Anderson KC Leukemia 22(4):842-9 FI: 8.296 (Q1) European Myeloma Network. Report of the European Myeloma Network on multiparametric flow cytometry in multiple myeloma and related disorders Rawstron AC, Orfao A, Beksac M, Bezdickova L, Brooimans RA, Bumbea H, Dalva K, Fuhler G, Gratama J, Hose D, Kovarova L, Lioznov M, Mateo G, Morilla R, Mylin AK, Omedé P, Pellat-Deceunynck C, Perez Andres M, Petrucci M, Ruggeri M, Rymkiewicz G, Schmitz A, Schreder M, Seynaeve C, Spacek M, de Tute RM, Van Valckenborgh E, Weston-Bell N, Owen RG, San Miguel JF, Sonneveld P, Johnsen HE. Haematologica 93(3):431-8 FI: 6.416 (Q1) Expression of c-kit isoforms in multiple myeloma: differences in signalling and drug sensitivity Montero JC, López-Pérez R, San Miguel JF, Pandiella A. Haematologica 93(6):851-9. FI: 6.416 (Q1) for the Doxil-Mmy-3001 Study investigators Pegylated liposomal doxorubicin plus bortezomib in relapsed or refractory multiple myeloma: efficacy and safety in patients with renal function impairment Bladé J, Sonneveld P, San Miguel JF, Sutherland HJ, Hajek R, Nagler A, Spencer A, Robak T, Cibeira MT, Zhuang SH, Harousseau JL, Orlowski RZ Clinical Lymphoma & Myeloma 8(6):352-5. FI: 1.130 (Q4) GEM (Grupo Español de MM)/PETHEMA (Programa para el Estudio de la Terapéutica en Hemopatías Malignas) Cooperative Study Groups. Multiparameter flow cytometric remission is the most relevant prognostic factor for multiple myeloma patients who undergo autologous stem cell transplantation Paíva B, Vidriales MB, Cervero J, Mateo G, Pérez JJ, Montalbán MA, Sureda A, Montejano L, G Gutiérrez NC, García de Coca A, de las Heras N, Mateos MV, López-Berges MC, García-Boyero R, Galende J, Hernández J, Palomera L, Carrera D, Martínez R, de la Rubia J, Martin A, Bladé J, Lahuerta JJ, Orfao A, San Miguel JF Blood 112(10):4017-23. FI: 10.555 (Q1) Individualizing treatment of patients with myeloma in the era of novel agents San Miguel JF, Harousseau JL, Joshua D, Anderson KC. Journal of Clinical Oncology 26(16):2761-6. FI: 17.793 (Q1) Influence of Pre-and Post Transplantation responses on outcome of patients with multiple myeloma: sequential improvement of response and achievement of complete response are associated with longer survival Lahuerta JJ, Mateos MV, Martínez-López J, Rosiñol L, Sureda A, de la Rubia J, García-Laraña J, Martínez R, Hernández-García MT, Carrera D, Besalduch J, de Arriba F, Ribera JM, Escoda L, Hernández-Ruiz B, García-Frade J, Rivas-González C, Alegre A, Bladé J, San Miguel JF. British Journal of Haematology 143(4):511-9. FI: 4.597 (Q1) International Myeloma Working Group. Prevention of thalidomide and lenalidomide associated thrombosis in myeloma Palumbo A, Rajkumar SV, Dimopoulos MA, Richardson PG, San Miguel JF, Barlogie B, Harousseau J, Zonder JA, Cavo M, Zangari M, Attal M, Belch A, Knop S, Joshua D, Sezer O, Ludwig H, Vesole D, Bladé J, Kyle R, Westin J, Weber D, Bringhen S, Niesvizky R, Waage A, von Lilienfeld-Toal M, Lonial S, Morgan GJ, Orlowski RZ, Shimizu K, Anderson KC, Boccadoro M, Durie BG, Sonneveld P, Hussein MA Leukemia 22(2):414-23 FI: 8.296 (Q1) Low expression of ZHX2, but not RCBTB2 or RAN, is associated with poor outcome in multiple myeloma Armellini A, Sarasquete ME, García Sanz R, Chillón MC, Balanzategui A, Alcoceba M, Fuertes M, López R, Hernández JM, Fernández-Calvo J, Sierra M, Megido M, Orfao A, Gutiérrez NC, González M, San Miguel JF. British Journal of Haematology 141(2):212-5. FI: 4.597 (Q1) Myeloma in patients under age 50 presents with more favorable features and shows better survival: an analysis of 10,549 patients from the International Myeloma Working Group Ludwig H, Durie BG, Bolejack V, Turesson I, Kyle RA, Bladé J, Fonseca R, Dimopoulos M, Shimizu K, San Miguel JF, Westin J, Harousseau JL, Beksac M, Boccadoro M, Palumbo A, Barlogie B, Shustik C, Cavo M, Joshua D, Attal M, Sonneveld P, Crowley J. Blood 111(8):4039-47 FI: 10.555 (Q1)
|
